2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy
July 25, 2019 07:00 ET | Capricor Therapeutics, Inc.
--Independent Data Safety Monitoring Board recommends to continue HOPE-2 study-- --Capricor to resume treating currently enrolled patients-- LOS ANGELES, July 25, 2019 (GLOBE NEWSWIRE) -- Capricor...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy
July 17, 2019 07:00 ET | Capricor Therapeutics, Inc.
-- Conference Call Today at 1 PM ET/10 AM PT --                                                   LOS ANGELES, July 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) announced...
2017 Capricor Final Logo v2@0.5x.png
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA
January 22, 2019 07:00 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it had positive outcomes in its comprehensive...
2017 Capricor Final Logo v2@0.5x.png
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
November 12, 2018 07:00 ET | Capricor Therapeutics, Inc.
Focus will be on Milestones for Development and Commercialization CAP-1002 Therapy for Duchenne Muscular Dystrophy LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics to Participate in Upcoming Conferences  
October 22, 2018 07:00 ET | Capricor Therapeutics, Inc.
Presentations to Focus on Company’s Exosome-based and Duchenne Muscular Dystrophy Therapies LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Linda Marbán, Ph.D, CEO of Capricor Therapeutics, Inc....
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
October 03, 2018 07:00 ET | Capricor Therapeutics, Inc.
LA JOLLA, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) will provide a presentation at the 2018 Cell & Gene Meeting on the Mesa today on its cell therapy,...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 09, 2018 16:00 ET | Capricor Therapeutics, Inc.
To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics to Present at PPMD Annual Conference
June 28, 2018 07:00 ET | Capricor Therapeutics, Inc.
LOS ANGELES, June 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics’ (NASDAQ:CAPR) chief medical officer, Deborah Ascheim, M.D., will present a corporate overview at the Parents Project Muscular...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics to Present at the 2018 BIO International Convention in Boston
May 29, 2018 07:00 ET | Capricor Therapeutics, Inc.
LOS ANGELES, May 29, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare disorders,...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 10, 2018 16:00 ET | Capricor Therapeutics, Inc.
HOPE-2 Clinical Trial is Currently Enrolling Patients Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 10, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a...